A meta-analysis of over 20 studies in HCC prior to 2015 revealed that while promising, tissue candidate gene-derived markers generally do not perform sufficiently well for clinical test development unless coupled with AFP 49. The gene discussed is AFP; the disease is hepatocellular carcinoma.